SUPPLEMENTARY MATERIAL

Figure S1. CD34⁺-derived mast cells characterization. **A)** FcεRI and KIT expression of MCs after 7 weeks. **B)** May Grünwald Giemsa staining of huMCs. **C)** Degranulation measured by β-hexosaminidase assay. PMA and Ionomycin were used as a positive control (n=3). Results are expressed as mean ± SD. Significance was determined using 1-way ANOVA with Dunkey's multiple comparison analysis. *P*<0.05 was considered significant. **P*<0.05; ***P*<0.01. Figure shows a representative example. STV= Streptavidin.



doi: 10.18176/jiaci.0995

Figure S2. Correlation between degranulation by $CD63^+$ and PGD_2 secretion. **A)** MCs from healthy volunteers. **B)** MCs from sensitized patients. **C)** MCs from anaphylaxis patients. Correlations were calculated by using Pearson R values. $P<0.05$ was considered significant.



doi: 10.18176/jiaci.0995

Figure S3. Gating strategy for $T_{FH}13$ cells. Representative flow pot of PBMCs from an LTP-allergic patient stimulated with PMA and Ionomycin.



doi: 10.18176/jiaci.0995

Figure S4. Sera from anaphylaxis patients induce a higher cytokine secretion. Cytokine multiplex assay was performed in CD34^{+}-derived mast cells from anaphylaxis (n=5) and sensitized patients (n=5). Results are expressed as mean ± SD. Significance was determined using a T-test with Welch's correction. *P*<0.05 was considered significant. MC=Mast cells; A=Anaphylaxis; S=Sensitized.



doi: 10.18176/jiaci.0995